Barely Significant
← all excerpts

Vortioxetine <i>versus</i> SSRI/SNRI with Pregabalin Augmentation in Treatment-Resistant Burning Mouth Syndrome: A Prospective Clinical Trial.

Curr Neuropharmacol · 2025 · PMC12163466 · PMID 40016875

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

moderately significantno p-value reported
The beta coefficient for the use of Paroxetine is 1.66, with an OR of 5.24 and a moderately significant p-value of 0.046.

also in 2,174 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.